The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.

The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.

The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...